Assyro AI

Orange Book product · Brand (NDA)

EVRYSDI

RISDIPLAM

Brand (NDA)NDA 213535RX GENENTECH INC

At a glance

Aug 07, 2020

Approved

Brand (NDA)

Application

Not listed

TE code

7

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 07, 2020

    5 yr 11 mo ago

  2. Today

  3. Exclusivity ends · M-270

    New use / labeling-change exclusivity (3 years)

    Oct 03, 2026

    in 4 mo

  4. Exclusivity ends · ODE-334

    Orphan-drug exclusivity (7 years)

    Aug 07, 2027

    in 1 yr 2 mo

  5. Exclusivity ends · ODE-400

    Orphan-drug exclusivity (7 years)

    May 27, 2029

    in 3 yr

  6. Patent 9586955 expires

    Listed drug substance patent expiration.

    Feb 08, 2033

    in 6 yr 9 mo

  7. Patent 9969754 expires

    Listed drug substance patent expiration.

    May 11, 2035

    in 9 yr

  8. Patent 11827646 expires

    Listed method-of-use patent (U-1943) expiration.

    Jan 25, 2036

    in 9 yr 9 mo

  9. Patent 11938136 expires

    Listed drug product patent expiration.

    Nov 08, 2036

    in 10 yr 7 mo

  10. Patent 12350273 expires

    Listed method-of-use patent (U-1943) expiration.

    Oct 01, 2038

    in 12 yr 6 mo

  11. Patent 11534444 expires

    Listed method-of-use patent (U-1943) expiration.

    Oct 04, 2038

    in 12 yr 6 mo

  12. Patent 12122789 expires

    Listed drug substance patent expiration.

    Apr 15, 2041

    in 15 yr

Pharmaceutical detail

Active ingredient

RISDIPLAM

Strength

0.75MG/ML

Dosage form

FOR SOLUTION

Route

ORAL

TE code

Not listed

Application

NDA 213535

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (3)

  • M-270New use / labeling-change exclusivity (3 years)

    Oct 03, 2026

    in 4 mo

  • ODE-334Orphan-drug exclusivity (7 years)

    Aug 07, 2027

    in 1 yr 2 mo

  • ODE-400Orphan-drug exclusivity (7 years)

    May 27, 2029

    in 3 yr

Listed patents (7)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9586955Feb 08, 2033in 6 yr 9 mo
SubstanceProduct
9969754May 11, 2035in 9 yr
SubstanceProductU-1943
11827646Jan 25, 2036in 9 yr 9 mo
U-1943
11938136Nov 08, 2036in 10 yr 7 mo
Product
12350273Oct 01, 2038in 12 yr 6 mo
U-1943
11534444Oct 04, 2038in 12 yr 6 mo
U-1943
12122789Apr 15, 2041in 15 yr
SubstanceProduct
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.